Asia Pacific Endomyocardial Biopsy Devices Market Size and Forecast (2021

Description

List of Tables

The Asia Pacific Endomyocardial Biopsy Devices Market is projected to expand from US$ 47,079.0 Thousand in 2025 to US$ 68,924.4 Thousand by 2034. The market is expected to register a CAGR of 4.3% between 2026 and 2034.

Executive Summary and Asia Pacific Endomyocardial Biopsy Devices Market Analysis

The Asia Pacific endomyocardial biopsy devices market is experiencing growth due to the rising prevalence of cardiovascular diseases, improvements in healthcare infrastructure, and increasing government and regulatory emphasis on timely diagnosis and effective disease management. Countries such as China, Japan, India, and South Korea are reporting increasing cases of heart failure and cardiomyopathies, strengthening the need for reliable myocardial diagnostic technologies, including endomyocardial biopsy devices.

Regulatory authorities across the region, including the National Medical Products Administration (NMPA), Pharmaceuticals and Medical Devices Agency (PMDA), and Central Drugs Standard Control Organization (CDSCO), are progressively improving regulatory processes and adopting standards that are increasingly consistent with international requirements. These developments are creating a more favorable environment for multinational medical device companies to establish and expand their regional presence. Prominent manufacturers such as Abbott Laboratories, Medtronic plc, and Boston Scientific Corporation are strengthening their operations through strategic partnerships, regional manufacturing initiatives, and continuous product development.

At the same time, the increasing number of catheterization laboratories, greater adoption of minimally invasive cardiac interventions, and incorporation of advanced imaging technologies are supporting the deployment of sophisticated biopsy systems. These developments are contributing to increased adoption across both mature healthcare markets and rapidly developing economies throughout Asia Pacific.

Strategic Insights

Asia Pacific Endomyocardial Biopsy Devices Market Segmentation Analysis

By Product Type, the Asia Pacific Endomyocardial Biopsy Devices Market is divided into Biopsy Forceps and Catheters, Guidance Systems, and Accessories. The Biopsy Forceps and Catheters segment accounted for the leading market share in 2025.

By Biopsy Forceps and Catheters, the market is classified into Standard Endomyocardial Biopsy Forceps and Flexible Biopsy Catheters. The Standard Endomyocardial Biopsy Forceps segment dominated the market in 2025.

By Guidance Systems, the market is categorized into Fluoroscopy-guided Systems, Echocardiography-guided Systems, and Emerging Robotic Navigation Systems. The Fluoroscopy-guided Systems segment held the dominant position in 2025.

By Accessories, the market is segmented into Introducer Sheaths, Guidewires, and Localization Tools. The Introducer Sheaths segment represented the largest share in 2025.

By Guidance Technique, the Asia Pacific Endomyocardial Biopsy Devices Market includes Fluoroscopy-guided EMB, Echocardiography-guided EMB, and Hybrid Techniques. The Fluoroscopy-guided EMB segment led the market in 2025.

By Application, the market is segmented into Transplant Rejection Monitoring, Myocarditis Diagnosis, Cardiomyopathy Evaluation, and Other Cardiac Pathologies. The Transplant Rejection Monitoring segment accounted for the largest market share in 2025.

By End User, the market is divided into Cardiac Centers and Hospitals, Diagnostic and Research Institutes, and Academic Institutions. The Cardiac Centers and Hospitals segment dominated the market in 2025.

Market Report Scope

Asia Pacific Endomyocardial Biopsy Devices Market Outlook

The growing number of clinical trials and research initiatives represents an important growth opportunity for the Asia Pacific endomyocardial biopsy devices market. Advances in cardiovascular research are creating a greater need for precise, reproducible, and clinically validated diagnostic technologies. Endomyocardial biopsy continues to serve as an important diagnostic reference for conditions including myocarditis, infiltrative cardiomyopathies, and cardiac transplant rejection. However, concerns associated with procedural risks and differences in diagnostic outcomes have historically restricted broader utilization.

The increasing number of investigator-led and industry-sponsored studies is encouraging efforts to standardize biopsy procedures, enhance catheter maneuverability, and incorporate real-time imaging technologies. Modalities such as echocardiography, fluoroscopy, and cardiac MRI are increasingly being evaluated for their ability to improve procedural guidance and diagnostic accuracy. Clinical trials are consequently playing a significant role in assessing the safety and tissue-sampling performance of newer EMB technologies while also supporting their application in emerging areas such as gene-expression profiling and precision medicine.

Academic institutions and organizations, including the National Institutes of Health and Mayo Clinic, are supporting research focused on myocardial tissue characterization and advanced cardiac diagnostics. Such research can contribute to increased biopsy procedure volumes and influence the development of clinical recommendations. As published evidence continues to demonstrate the clinical value of EMB for timely and accurate diagnosis, cardiologists are expected to show greater willingness to use advanced biopsy systems. This is likely to generate sustained demand for devices offering improved safety, flexibility, maneuverability, and compatibility with multiple imaging technologies.

From an industry standpoint, leading medical device manufacturers are using clinical research and collaborations to optimize their endomyocardial biopsy portfolios and facilitate wider market adoption. Companies including Medtronic and Abbott Laboratories have participated in research partnerships with major cardiac institutions to advance catheter steerability, catheter design, and integration with electrophysiology mapping technologies. Many of these developments undergo clinical evaluation before being introduced commercially, helping manufacturers demonstrate safety and procedural effectiveness.

Biotronik has also supported research related to cardiac diagnostics and device-based monitoring, contributing to broader improvements in cardiac care pathways that can complement EMB-related developments. Teleflex, meanwhile, continues to enhance biopsy forceps and catheter technologies by incorporating feedback from clinicians and procedural studies. These efforts are focused on improving tissue sample quality while minimizing procedure-related complications, including the risk of myocardial perforation.

In addition, collaborations between biotechnology companies and medical device manufacturers, including initiatives involving BioCardia, are examining the potential use of biopsy-derived tissue alongside regenerative medicine applications. Such developments are expanding the potential clinical utility of EMB beyond conventional diagnostic purposes. The increasing volume of clinical research helps reduce uncertainty surrounding the adoption of newer technologies while establishing a continuous cycle of product development, clinical validation, and commercialization. As a result, clinical trials and research are expected to remain a significant long-term growth factor for the endomyocardial biopsy devices market.

Asia Pacific Endomyocardial Biopsy Devices Market Country Insights

By country, the Asia Pacific Endomyocardial Biopsy Devices Market is segmented into China, Japan, India, Australia, South Korea, and the Rest of Asia Pacific. China held the largest market share in 2025.

The endomyocardial biopsy devices market in China is supported by the country's substantial cardiovascular disease burden, rapid modernization of hospitals, and increasing government spending on advanced cardiac healthcare infrastructure. China faces a significant incidence of coronary artery disease, heart failure, and cardiomyopathy, with contributing factors including population aging, urbanization, and lifestyle-related conditions such as hypertension and diabetes.

The increasing cardiovascular disease burden has resulted in a high volume of interventional cardiology procedures and strengthened the need for accurate technologies capable of evaluating myocardial tissue. The National Medical Products Administration (NMPA) oversees medical device regulation in the country and has been working toward greater alignment with international regulatory practices while facilitating the approval of innovative medical technologies.

Significant investments in catheterization laboratories and specialized cardiac facilities, particularly across tier-1 and tier-2 cities, are improving the availability of advanced cardiac diagnostic and interventional procedures. Multinational and domestic companies, including Medtronic plc, Abbott Laboratories, and MicroPort Scientific, are expanding their Chinese operations through localization initiatives, strategic partnerships, and collaborations with healthcare institutions.

The Chinese Society of Cardiology also contributes to professional education, clinical training, and standardization of interventional cardiac procedures. In parallel, healthcare reforms are improving access to minimally invasive diagnostic technologies, supporting the broader adoption of endomyocardial biopsy procedures across China's expanding cardiac healthcare ecosystem.

Asia Pacific Endomyocardial Biopsy Devices Market Company Profiles

Major companies participating in the Asia Pacific Endomyocardial Biopsy Devices Market include Terumo Corp, Argon Medical Devices, Koninklijke Philips NV, GE HealthCare Technologies Inc., Siemens Healthineers AG, Cordis Corp, Scholten Surgical Instruments, Inc., Changzhou Lookmed Medical Instrument Co., Ltd., FEHLING INSTRUMENTS GmbH, and WILDmedical GmbH.

These market participants are implementing strategies such as regional expansion, product development, technological innovation, strategic partnerships, mergers, and acquisitions. Through these initiatives, companies are seeking to strengthen their product portfolios, address evolving clinical requirements, broaden their geographic reach, and improve their overall market position.

Product Code: TIPRE00043895

1. Executive Summary

1.1 Analyst Market Outlook

2. Global Endomyocardial Biopsy Devices Market Landscape

2.1 Overview
2.2 Value Chain Analysis
2.3 Supply Chain Analysis
- 2.3.1 List of Manufacturers/Suppliers
- 2.3.2 List of Potential Customers (Upto 50)
2.4 Porter's Five Forces Analysis
2.5 PEST Analysis

3. Competitive Landscape

3.1 Company Benchmarking by Key Players
3.2 Market Share Analysis, 2025 - By Key Players
3.3 Market Concentration

4. Asia Pacific Endomyocardial Biopsy Devices Market - Key Industry Dynamics

4.1 Market Drivers
4.2 Market Restraints
4.3 Market Opportunities
4.4 Future Trends
4.5 Impact of Drivers and Restraints:

5. Endomyocardial Biopsy Devices Market - Asia Pacific Analysis

5.1 Asia Pacific Endomyocardial Biopsy Devices Market Revenue (US$ Thousand), 2021 - 2034
5.2 Asia Pacific Endomyocardial Biopsy Devices Market Revenue Forecast and Analysis

6. Asia Pacific Endomyocardial Biopsy Devices Market Revenue Analysis - by Product Type

6.1 Asia Pacific Endomyocardial Biopsy Devices Market Forecast and Analysis by Product Type
- 6.1.1 Biopsy Forceps and Catheters
  - 6.1.1.1 Overview
  - 6.1.1.2 Biopsy Forceps and Catheters: Asia Pacific Endomyocardial Biopsy Devices Market - Revenue and Forecast, 2021 - 2034 (US$ Thousand)
- 6.1.2 Guidance Systems
  - 6.1.2.1 Overview
  - 6.1.2.2 Guidance Systems: Asia Pacific Endomyocardial Biopsy Devices Market - Revenue and Forecast, 2021 - 2034 (US$ Thousand)
- 6.1.3 Accessories
  - 6.1.3.1 Overview
  - 6.1.3.2 Accessories: Asia Pacific Endomyocardial Biopsy Devices Market - Revenue and Forecast, 2021 - 2034 (US$ Thousand)

7. Asia Pacific Endomyocardial Biopsy Devices Market Revenue Analysis - by Biopsy Forceps And Catheters

7.1 Asia Pacific Endomyocardial Biopsy Devices Market Forecast and Analysis by Biopsy Forceps And Catheters
- 7.1.1 Standard endomyocardial biopsy forceps
  - 7.1.1.1 Overview
  - 7.1.1.2 Standard endomyocardial biopsy forceps: Asia Pacific Endomyocardial Biopsy Devices Market - Revenue and Forecast, 2021 - 2034 (US$ Thousand)
- 7.1.2 Flexible biopsy catheters
  - 7.1.2.1 Overview
  - 7.1.2.2 Flexible biopsy catheters: Asia Pacific Endomyocardial Biopsy Devices Market - Revenue and Forecast, 2021 - 2034 (US$ Thousand)

8. Asia Pacific Endomyocardial Biopsy Devices Market Revenue Analysis - by Guidance Systems - Product Type

8.1 Asia Pacific Endomyocardial Biopsy Devices Market Forecast and Analysis by Guidance Systems - Product Type
- 8.1.1 Fluoroscopy-guided systems
  - 8.1.1.1 Overview
  - 8.1.1.2 Fluoroscopy-guided systems: Asia Pacific Endomyocardial Biopsy Devices Market - Revenue and Forecast, 2021 - 2034 (US$ Thousand)
- 8.1.2 Echocardiography-guided systems
  - 8.1.2.1 Overview
  - 8.1.2.2 Echocardiography-guided systems: Asia Pacific Endomyocardial Biopsy Devices Market - Revenue and Forecast, 2021 - 2034 (US$ Thousand)
- 8.1.3 Emerging robotic navigation systems
  - 8.1.3.1 Overview
  - 8.1.3.2 Emerging robotic navigation systems: Asia Pacific Endomyocardial Biopsy Devices Market - Revenue and Forecast, 2021 - 2034 (US$ Thousand)

9. Asia Pacific Endomyocardial Biopsy Devices Market Revenue Analysis - by Accessories

9.1 Asia Pacific Endomyocardial Biopsy Devices Market Forecast and Analysis by Accessories
- 9.1.1 Introducer sheaths
  - 9.1.1.1 Overview
  - 9.1.1.2 Introducer sheaths: Asia Pacific Endomyocardial Biopsy Devices Market - Revenue and Forecast, 2021 - 2034 (US$ Thousand)
- 9.1.2 Guidewires
  - 9.1.2.1 Overview
  - 9.1.2.2 Guidewires: Asia Pacific Endomyocardial Biopsy Devices Market - Revenue and Forecast, 2021 - 2034 (US$ Thousand)
- 9.1.3 Localization tools
  - 9.1.3.1 Overview
  - 9.1.3.2 Localization tools: Asia Pacific Endomyocardial Biopsy Devices Market - Revenue and Forecast, 2021 - 2034 (US$ Thousand)

10. Asia Pacific Endomyocardial Biopsy Devices Market Revenue Analysis - by Guidance Technique

10.1 Asia Pacific Endomyocardial Biopsy Devices Market Forecast and Analysis by Guidance Technique
- 10.1.1 Fluoroscopy-guided EMB
  - 10.1.1.1 Overview
  - 10.1.1.2 Fluoroscopy-guided EMB: Asia Pacific Endomyocardial Biopsy Devices Market - Revenue and Forecast, 2021 - 2034 (US$ Thousand)
- 10.1.2 Echocardiography-guided EMB
  - 10.1.2.1 Overview
  - 10.1.2.2 Echocardiography-guided EMB: Asia Pacific Endomyocardial Biopsy Devices Market - Revenue and Forecast, 2021 - 2034 (US$ Thousand)
- 10.1.3 Hybrid techniques
  - 10.1.3.1 Overview
  - 10.1.3.2 Hybrid techniques: Asia Pacific Endomyocardial Biopsy Devices Market - Revenue and Forecast, 2021 - 2034 (US$ Thousand)

11. Asia Pacific Endomyocardial Biopsy Devices Market Revenue Analysis - by Application

11.1 Asia Pacific Endomyocardial Biopsy Devices Market Forecast and Analysis by Application
- 11.1.1 Transplant rejection monitoring
  - 11.1.1.1 Overview
  - 11.1.1.2 Transplant rejection monitoring: Asia Pacific Endomyocardial Biopsy Devices Market - Revenue and Forecast, 2021 - 2034 (US$ Thousand)
- 11.1.2 Myocarditis diagnosis
  - 11.1.2.1 Overview
  - 11.1.2.2 Myocarditis diagnosis: Asia Pacific Endomyocardial Biopsy Devices Market - Revenue and Forecast, 2021 - 2034 (US$ Thousand)
- 11.1.3 Cardiomyopathy evaluation
  - 11.1.3.1 Overview
  - 11.1.3.2 Cardiomyopathy evaluation: Asia Pacific Endomyocardial Biopsy Devices Market - Revenue and Forecast, 2021 - 2034 (US$ Thousand)
- 11.1.4 Other cardiac pathologies
  - 11.1.4.1 Overview
  - 11.1.4.2 Other cardiac pathologies: Asia Pacific Endomyocardial Biopsy Devices Market - Revenue and Forecast, 2021 - 2034 (US$ Thousand)

12. Asia Pacific Endomyocardial Biopsy Devices Market Revenue Analysis - by End User

12.1 Asia Pacific Endomyocardial Biopsy Devices Market Forecast and Analysis by End User
- 12.1.1 Cardiac centers and hospitals
  - 12.1.1.1 Overview
  - 12.1.1.2 Cardiac centers and hospitals: Asia Pacific Endomyocardial Biopsy Devices Market - Revenue and Forecast, 2021 - 2034 (US$ Thousand)
- 12.1.2 Diagnostic and research institutes
  - 12.1.2.1 Overview
  - 12.1.2.2 Diagnostic and research institutes: Asia Pacific Endomyocardial Biopsy Devices Market - Revenue and Forecast, 2021 - 2034 (US$ Thousand)
- 12.1.3 Academic institutions
  - 12.1.3.1 Overview
  - 12.1.3.2 Academic institutions: Asia Pacific Endomyocardial Biopsy Devices Market - Revenue and Forecast, 2021 - 2034 (US$ Thousand)

13. Asia Pacific Endomyocardial Biopsy Devices Market - Country Analysis

13.1 Asia Pacific
- 13.1.1 Asia Pacific Endomyocardial Biopsy Devices Market Forecast and Analysis - by Country
  - 13.1.1.1 China Market
    - 13.1.1.1.1 China: Asia Pacific Endomyocardial Biopsy Devices Market - Revenue and Forecast, 2021 - 2034 (US$ Thousand)
    - 13.1.1.1.2 China: Asia Pacific Endomyocardial Biopsy Devices Market - By Segmentation
      - 13.1.1.1.2.1 Product Type
      - 13.1.1.1.2.2 Biopsy Forceps And Catheters
      - 13.1.1.1.2.3 Guidance Systems - Product Type
      - 13.1.1.1.2.4 Accessories
      - 13.1.1.1.2.5 Guidance Technique
      - 13.1.1.1.2.6 Application
      - 13.1.1.1.2.7 End User
  - 13.1.1.2 Japan Market
    - 13.1.1.2.1 Japan: Asia Pacific Endomyocardial Biopsy Devices Market - Revenue and Forecast, 2021 - 2034 (US$ Thousand)
    - 13.1.1.2.2 Japan: Asia Pacific Endomyocardial Biopsy Devices Market - By Segmentation
      - 13.1.1.2.2.1 Product Type
      - 13.1.1.2.2.2 Biopsy Forceps And Catheters
      - 13.1.1.2.2.3 Guidance Systems - Product Type
      - 13.1.1.2.2.4 Accessories
      - 13.1.1.2.2.5 Guidance Technique
      - 13.1.1.2.2.6 Application
      - 13.1.1.2.2.7 End User
  - 13.1.1.3 India Market
    - 13.1.1.3.1 India: Asia Pacific Endomyocardial Biopsy Devices Market - Revenue and Forecast, 2021 - 2034 (US$ Thousand)
    - 13.1.1.3.2 India: Asia Pacific Endomyocardial Biopsy Devices Market - By Segmentation
      - 13.1.1.3.2.1 Product Type
      - 13.1.1.3.2.2 Biopsy Forceps And Catheters
      - 13.1.1.3.2.3 Guidance Systems - Product Type
      - 13.1.1.3.2.4 Accessories
      - 13.1.1.3.2.5 Guidance Technique
      - 13.1.1.3.2.6 Application
      - 13.1.1.3.2.7 End User
  - 13.1.1.4 Australia Market
    - 13.1.1.4.1 Australia: Asia Pacific Endomyocardial Biopsy Devices Market - Revenue and Forecast, 2021 - 2034 (US$ Thousand)
    - 13.1.1.4.2 Australia: Asia Pacific Endomyocardial Biopsy Devices Market - By Segmentation
      - 13.1.1.4.2.1 Product Type
      - 13.1.1.4.2.2 Biopsy Forceps And Catheters
      - 13.1.1.4.2.3 Guidance Systems - Product Type
      - 13.1.1.4.2.4 Accessories
      - 13.1.1.4.2.5 Guidance Technique
      - 13.1.1.4.2.6 Application
      - 13.1.1.4.2.7 End User
  - 13.1.1.5 South Korea Market
    - 13.1.1.5.1 South Korea: Asia Pacific Endomyocardial Biopsy Devices Market - Revenue and Forecast, 2021 - 2034 (US$ Thousand)
    - 13.1.1.5.2 South Korea: Asia Pacific Endomyocardial Biopsy Devices Market - By Segmentation
      - 13.1.1.5.2.1 Product Type
      - 13.1.1.5.2.2 Biopsy Forceps And Catheters
      - 13.1.1.5.2.3 Guidance Systems - Product Type
      - 13.1.1.5.2.4 Accessories
      - 13.1.1.5.2.5 Guidance Technique
      - 13.1.1.5.2.6 Application
      - 13.1.1.5.2.7 End User
  - 13.1.1.6 Rest of Asia Pacific Market
    - 13.1.1.6.1 Rest of Asia Pacific: Asia Pacific Endomyocardial Biopsy Devices Market - Revenue and Forecast, 2021 - 2034 (US$ Thousand)
    - 13.1.1.6.2 Rest of Asia Pacific: Asia Pacific Endomyocardial Biopsy Devices Market - By Segmentation
      - 13.1.1.6.2.1 Product Type
      - 13.1.1.6.2.2 Biopsy Forceps And Catheters
      - 13.1.1.6.2.3 Guidance Systems - Product Type
      - 13.1.1.6.2.4 Accessories
      - 13.1.1.6.2.5 Guidance Technique
      - 13.1.1.6.2.6 Application
      - 13.1.1.6.2.7 End User

14 Endomyocardial Biopsy Devices Market Industry Landscape

15 - Key Company Profiles

15.1 Terumo Corp
- 15.1.1 Key Facts
- 15.1.2 Business Description
- 15.1.3 Products and Services
- 15.1.4 Financial Overview
- 15.1.5 SWOT Analysis
- 15.1.6 Key Developments
15.2 Argon Medical Devices
- 15.2.1 Key Facts
- 15.2.2 Business Description
- 15.2.3 Products and Services
- 15.2.4 Financial Overview
- 15.2.5 SWOT Analysis
- 15.2.6 Key Developments
15.3 Koninklijke Philips NV
- 15.3.1 Key Facts
- 15.3.2 Business Description
- 15.3.3 Products and Services
- 15.3.4 Financial Overview
- 15.3.5 SWOT Analysis
- 15.3.6 Key Developments
15.4 GE HealthCare Technologies Inc
- 15.4.1 Key Facts
- 15.4.2 Business Description
- 15.4.3 Products and Services
- 15.4.4 Financial Overview
- 15.4.5 SWOT Analysis
- 15.4.6 Key Developments
15.5 Siemens Healthineers AG
- 15.5.1 Key Facts
- 15.5.2 Business Description
- 15.5.3 Products and Services
- 15.5.4 Financial Overview
- 15.5.5 SWOT Analysis
- 15.5.6 Key Developments
15.6 Cordis Corp
- 15.6.1 Key Facts
- 15.6.2 Business Description
- 15.6.3 Products and Services
- 15.6.4 Financial Overview
- 15.6.5 SWOT Analysis
- 15.6.6 Key Developments
15.7 Scholten Surgical Instruments, Inc.
- 15.7.1 Key Facts
- 15.7.2 Business Description
- 15.7.3 Products and Services
- 15.7.4 Financial Overview
- 15.7.5 SWOT Analysis
- 15.7.6 Key Developments
15.8 Changzhou Lookmed Medical Instrument Co., Ltd.
- 15.8.1 Key Facts
- 15.8.2 Business Description
- 15.8.3 Products and Services
- 15.8.4 Financial Overview
- 15.8.5 SWOT Analysis
- 15.8.6 Key Developments
15.9 FEHLING INSTRUMENTS GmbH
- 15.9.1 Key Facts
- 15.9.2 Business Description
- 15.9.3 Products and Services
- 15.9.4 Financial Overview
- 15.9.5 SWOT Analysis
- 15.9.6 Key Developments
15.10 WILDmedical GmbH
- 15.10.1 Key Facts
- 15.10.2 Business Description
- 15.10.3 Products and Services
- 15.10.4 Financial Overview
- 15.10.5 SWOT Analysis
- 15.10.6 Key Developments

16. Appendix

16.1 Glossary
16.2 Research Methodology and Approach
- 16.2.1 Secondary Research
- 16.2.2 Primary Research
- 16.2.3 Market Estimation Approach
  - 16.2.3.1 Supply Side Analysis
  - 16.2.3.2 Demand Side Analysis
- 16.2.4 Research Assumptions and Limitations
- 16.2.5 Currency Conversion
16.3 About The Insight Partners
16.4 Market Intelligence Cloud